Clinical Trials Logo

Filter by:
NCT ID: NCT01175174 Completed - Asthma Clinical Trials

Clinical, Airway Inflammatory, and HRA Phenotypes, in Preschool Children With Acute Asthmatic Attack Presenting to the ED.

Start date: January 2009
Phase: N/A
Study type: Observational

Clinical, Airway Inflammatory, and HRA Phenotypes, in preschool children with acute asthmatic attack presenting to the ED. Background: Children under the age of 5 years have the highest hospitalization rate of asthma. The most common causes of acute exacerbations of asthma requiring urgent medical care are viral respiratory infections. Most of these children < 6 y old are not atopic. The inflammatory response to these mostly viral-induced asthmatic attacks is not well characterized in the literature. Moreover it is not known whether different kind of inflammatory responses exist in this population and how this correlate to clinical outcomes and clinical phenotypes in preschool children presenting ti the ED with acute asthmatic attack. Therefore, the purpose of the present study is to: Investigate the characterization of induced sputum cytology in preschool children with acute asthmatic attack and whether there is correlation between specific sputum cytology and response to therapy and to investigate airways hyper-responsiveness to adenosine 5'-monophosphate and to metacholine in pre school children 2-6 y old at 2 weeks and at 3 month following acute asthmatic exacerbation and look for correlation with response to treatment and sputum cytology. Clinical phenotypes of this patient population will also be investigated.

NCT ID: NCT01174563 Completed - Clinical trials for Non-Squamous Non-Small Cell Lung Cancer

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

Start date: May 23, 2011
Phase: Phase 2
Study type: Interventional

This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) receiving first-line therapy for advanced disease. Participants will receive Tarceva at a dose of 150 mg daily orally, with dose adjustments according to protocol depending on toxicity. Anticipated time on study treatment is until disease progression, unacceptable toxicity, or withdrawal due to any reason.

NCT ID: NCT01174537 Withdrawn - Glioblastoma Clinical Trials

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free disease and posits that it will be extended.

NCT ID: NCT01174355 Completed - Clinical trials for Attention Deficit and Hyperactivity Disorder

A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).

NCT ID: NCT01174342 Completed - Clinical trials for Intraocular Pressure

Effect of Child Delivery on Intraocular Pressure

Start date: August 2010
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the effect of child delivery on the intraocular pressure in healthy women.

NCT ID: NCT01173744 Recruiting - Clinical trials for Intertrochanteric Femoral Fractures

Comparison of Gamma Nail Versus Dynamic Hip Screw for the Treatment of Unstable Intertrochanteric Fractures

Start date: July 2010
Phase: N/A
Study type: Interventional

The objective of the study is to examine the treatment of unstable Intertrochanteric fractures with the short Gamma nail, compared to the use of the dynamic hip screw (DHS). This is a prospective study. Sixty patients with unstable Intertrochanteric fractures will be randomized to be treated using either Gamma nail or DHS. The patients will be followed for 12 months. The primary endpoint is the clinical outcome as measured by the Merle d'Aubigne and Postelhip score.

NCT ID: NCT01172834 Not yet recruiting - Healthy Clinical Trials

The Possible Influence of Health Promotion Coaching on Health Related and Organizational Outcomes Among Nurses

Start date: January 2011
Phase: N/A
Study type: Interventional

Strong evidence shows that physical activity (PA) has favorable psychological and health related outcomes. However, most employees do not perform enough PA to achieve health and well being benefits. Worksite interventions aimed at improving PA often yield modest effect sizes, and their theoretical ground is not profound. The Health Action Process Approach (HAPA), is a novel comprehensive theoretical model for health behavior change, that hasn't been studied as a whole in a worksite intervention study. The objectives of the proposed study are: 1. To develop a coaching-based group intervention that will be both grounded in theory (HAPA) as well as applicable. 2. To evaluate the feasibility of conducting this intervention among employed hospital nurses, using a randomized controlled design, interviews and other evaluation procedures. The proposed study will offer the most comprehensive empirical test to date of the full HAPA model.

NCT ID: NCT01171820 Completed - Clinical trials for Coronary Artery Disease

SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)

Start date: November 2006
Phase: Phase 4
Study type: Interventional

The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery lesions in patients (Diabetic sub-study).

NCT ID: NCT01171443 Not yet recruiting - Multiple Myeloma Clinical Trials

The Pathophysiology of Bortezomib Induced Peripheral Neuropathy

BIPN
Start date: August 2010
Phase: N/A
Study type: Observational

Since the pathophysiology of BIPN still remains unclear, in the present study we are going to assess the development of BIPN in newly diagnosed myeloma patients, based on clinical neurological examination and electrophysiological study (EMG) and trying to find out if there is any relationship between oxidative stress generation measured by serum malonyldialdehyde - (MDA) and urinary isoprostane, and the development of BIPN, which can explain important part of the BIPN pathophysiology and can suggest new ideas of treatment and prophylactic strategies of peripheral neuropathy.

NCT ID: NCT01171326 Completed - Impetigo Clinical Trials

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Start date: August 2010
Phase: Phase 2
Study type: Interventional

Impetigo is a common, highly infectious skin disease caused by bacterial infection and characterized by crusting skin lesions. It is most common in children, particularly children in unhealthy living conditions. In adults, it may follow other skin disorders. Impetigo is caused primarily by the bacteria Streptococcus pyogenes and/or Staphylococcus aureus, which can also be isolated from impetigo lesions. This is a pilot phase II study to evaluate the tolerability and safety and to monitor the clinical efficacy of Topical Minocycline Foam FXFM244 in impetigo patients.